Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kosmos Energy Ltd. Common Shares (DE) (KOS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Kosmos Energy Ltd. Common Shares (DE)Trade
Travere Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Kosmos Energy Ltd. Common Shares (DE) vs Travere Therapeutics Inc. Common Stock — how do they compare? Kosmos Energy Ltd. Common Shares (DE) trades at $2.71 (market cap $1.66B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.9× Kosmos Energy Ltd. Common Shares (DE)'s market cap, and Kosmos Energy Ltd. Common Shares (DE) is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kosmos Energy Ltd. Common Shares (DE) for 0 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.

KOSTVTX
Market Cap
$1.66B$4.88B
Volume
7,535,3441,668,577
Sector
EnergyHealth
52-Week High
$3.27$67.52
52-Week Low
$0.87$26.79
Typical Hold Time
0 Days0 Days
Enterprise Value
$4.30B$5.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kosmos Energy Ltd. Common Shares (DE)

No Aura AI signal available yet.

Travere Therapeutics Inc. Common Stock

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KOS
100% Buy0% Sell
Avg holding period · 0 Days
TVTX
100% Buy0% Sell
Avg holding period · 0 Days

About Kosmos Energy Ltd. Common Shares (DE)

Kosmos Energy Ltd. is a deepwater oil and gas exploration and production company with operations offshore Ghana, Equatorial Guinea, Mauritania, and Senegal in West Africa.

Read more on KOS →

About Travere Therapeutics Inc. Common Stock

Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.

Read more on TVTX →